Rhythm Pharmaceuticals (RYTM) Non-Current Debt (2022 - 2026)

Rhythm Pharmaceuticals (RYTM) has 5 years of Non-Current Debt data on file, last reported at $98.3 million in Q1 2026.

• On a quarterly basis, Non-Current Debt fell 8.89% year-over-year to $98.3 million in Q1 2026; TTM through Mar 2026 was $98.3 million, a 8.89% decrease from a year earlier, with the FY2025 full-year figure at $100.9 million, down 6.82% from the prior year.
• Non-Current Debt for Q1 2026 stood at $98.3 million, down from $100.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for RYTM reached as high as $108.3 million in Q4 2024 and fell as low as $34.3 million in Q2 2022.
• Historically, Non-Current Debt has averaged $93.1 million across 5 years, with a median of $103.4 million in 2025.
• Across the five-year window, Non-Current Debt increased 2.0% in 2024 and decreased 8.89% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $73.0 million in 2022, then jumped by 45.48% to $106.1 million in 2023, then climbed by 2.0% to $108.3 million in 2024, then slipped by 6.82% to $100.9 million in 2025, then declined by 2.52% to $98.3 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $98.3 million in Q1 2026, $100.9 million in Q4 2025, and $103.4 million in Q3 2025.